Failed in phase 2
Elezanumab: slow disability worsening in relapsing and progressive MS
relapsing and progressive MS · Remyelination / oligodendrocyte repair
Controlled phase 2 trials did not meet their main goal for this group.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 208
How the verdict was reached
Negative in phase 2
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Elezanumab, phase 2 | Phase 2 | 208 | 2018 | Missed its main goal The primary endpoint of ORS was not met in either study. Paper abstract | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as Failed in phase 2
Related hypotheses
- Clemastine: repair myelin in relapsing and progressive MS
- Gsk239512: repair myelin in relapsing and progressive MS
- Elezanumab: slow disability worsening in primary progressive MS
- Elezanumab: slow disability worsening in secondary progressive MS
- Opicinumab: slow disability worsening in relapsing and progressive MS
- Clemastine: reduce relapses and new lesions in relapsing and progressive MS
- Gsk239512: reduce relapses and new lesions in relapsing and progressive MS
Assembled by software from public sources.